ArticleEndoscopy international open2026
Endoscopic papillectomy for ampullary tumors: Multicenter retrospective study.
Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Although endoscopic papillectomy is an established minimally invasive alternative to surgical resection for ampullary tumors, its technical aspects remain poorly defined. This study aimed to identify factors associated with piecemeal resection and recurrence-free survival after endoscopic papillectomy. Patients and methods: A multicenter, retrospective analysis of consecutive patients who underwent endoscopic papillectomy in six tertiary Polish centers between 2011 and 2023 was performed. Multivariable logistic and Cox regression models were applied. Results: A total of 192 patients were included. Adverse events occurred in 26.6% of patients. The most frequent were bleeding (17.3%) and acute pancreatitis (15.6%). En bloc resection was achieved in 66.1% of tumors. Larger tumor size (odds ratio [OR] 1.07 per mm increase; 95% confidence interval [CI] 1.02-1.12]; Conclusions: Larger tumors and piecemeal resection were independently associated with shorter recurrence-free survival. Optimization of technical aspects to achieve higher en bloc resection rates may be critical to reduce recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.